105 related articles for article (PubMed ID: 16393888)
1. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
2. Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study.
Dabbish E; Scoditti S; Shehata MNI; Ritacco I; Ibrahim MAA; Shoeib T; Sicilia E
J Comput Chem; 2024 Apr; 45(10):663-670. PubMed ID: 38088485
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Survival of Cellulose Sulphate-Encapsulated Cells and Metronomic Ifosfamide Control Tumour Growth in Pancreatic Cancer Models-A Prelude to Treating Solid Tumours Effectively in Pets and Humans.
Salmons B; Gunzburg WH
Life (Basel); 2023 Dec; 13(12):. PubMed ID: 38137959
[TBL] [Abstract][Full Text] [Related]
4. Possible role of acrolein in oxazaphosphorine-induced enhancement of immunological reactivity.
Blomgren H; Hallström M
Cancer Immunol Immunother; 1990; 31(4):221-5. PubMed ID: 2143101
[TBL] [Abstract][Full Text] [Related]
5. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
[TBL] [Abstract][Full Text] [Related]
6. Design of new oxazaphosphorine anticancer drugs.
Liang J; Huang M; Duan W; Yu XQ; Zhou S
Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide and cancer: golden anniversary.
Emadi A; Jones RJ; Brodsky RA
Nat Rev Clin Oncol; 2009 Nov; 6(11):638-47. PubMed ID: 19786984
[TBL] [Abstract][Full Text] [Related]
8. The history of the oxazaphosphorine cytostatics.
Brock N
Cancer; 1996 Aug; 78(3):542-7. PubMed ID: 8697402
[No Abstract] [Full Text] [Related]
9. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy.
Ahlmann M; Hempel G
Cancer Chemother Pharmacol; 2016 Oct; 78(4):661-71. PubMed ID: 27646791
[TBL] [Abstract][Full Text] [Related]
10. An overview of cyclophosphamide and ifosfamide pharmacology.
Fleming RA
Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
[TBL] [Abstract][Full Text] [Related]
11. An anniversary for cancer chemotherapy.
Hirsch J
JAMA; 2006 Sep; 296(12):1518-20. PubMed ID: 17003400
[No Abstract] [Full Text] [Related]
12. The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma.
Picher EA; Wahajuddin M; Barth S; Chisholm J; Shipley J; Pors K
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473371
[TBL] [Abstract][Full Text] [Related]
13. Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents.
Rushing BR
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686047
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective effect of taxifolin on cyclophosphamide-induced oxidative stress, inflammation, and apoptosis in mice: Involvement of Nrf2/HO-1 signaling.
Althunibat OY; Abukhalil MH; Jghef MM; Alfwuaires MA; Algefare AI; Alsuwayt B; Alazragi R; Abourehab MAS; Almuqati AF; Karimulla S; Aladaileh SH
Biomol Biomed; 2023 Jul; 23(4):649-660. PubMed ID: 36762432
[TBL] [Abstract][Full Text] [Related]
15. Açai Berry Attenuates Cyclophosphamide-Induced Damage in Genitourinary Axis-Modulating Nrf-2/HO-1 Pathways.
Siracusa R; D'Amico R; Fusco R; Impellizzeri D; Peritore AF; Gugliandolo E; Crupi R; Interdonato L; Cordaro M; Cuzzocrea S; Di Paola R
Antioxidants (Basel); 2022 Nov; 11(12):. PubMed ID: 36552563
[TBL] [Abstract][Full Text] [Related]
16. Efflux capacity and aldehyde dehydrogenase both contribute to CD8+ T-cell resistance to posttransplant cyclophosphamide.
Patterson MT; Nunes NS; Wachsmuth LP; Panjabi A; Fletcher RE; Khan SM; Dimitrova D; Kanakry JA; Luznik L; Kanakry CG
Blood Adv; 2022 Sep; 6(17):4994-5008. PubMed ID: 35819449
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI.
De Chiara L; Lugli G; Villa G; Raglianti V; Husain-Syed F; Ravaglia F; Romagnani P; Lazzeri E
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269781
[TBL] [Abstract][Full Text] [Related]
18. Polyphenol-rich extract of Ocimum gratissimum leaves prevented toxic effects of cyclophosphamide on the kidney function of Wistar rats.
Alabi QK; Akomolafe RO; Omole JG; Aturamu A; Ige MS; Kayode OO; Kajewole-Alabi D
BMC Complement Med Ther; 2021 Nov; 21(1):274. PubMed ID: 34727903
[TBL] [Abstract][Full Text] [Related]
19. Hidrox
Fusco R; Salinaro AT; Siracusa R; D'Amico R; Impellizzeri D; Scuto M; Ontario ML; Crea R; Cordaro M; Cuzzocrea S; Di Paola R; Calabrese V
Antioxidants (Basel); 2021 May; 10(5):. PubMed ID: 34068924
[TBL] [Abstract][Full Text] [Related]
20. Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma.
Swan D; Gurney M; Krawczyk J; Ryan AE; O'Dwyer M
Hemasphere; 2020 Apr; 4(2):e350. PubMed ID: 32309787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
